Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies - Wikidata - awgldk - TriplyDB

Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies

Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies

http://www.wikidata.org/entity/Q34753135

about

Virion Glycoprotein-Mediated Immune Evasion by Human Cytomegalovirus: a Sticky Virus Makes a Slick Getaway Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design Antigenic Characterization of the HCMV gH/gL/gO and Pentamer Cell Entry Complexes Reveals Binding Sites for Potently Neutralizing Human Antibodies A derivative of platelet-derived growth factor receptor alpha binds to the trimer of human cytomegalovirus and inhibits entry into fibroblasts and endothelial cells Human Cytomegalovirus gH/gL/gO Promotes the Fusion Step of Entry into All Cell Types, whereas gH/gL/UL128-131 Broadens Virus Tropism through a Distinct Mechanism.Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody.Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection.Vaccine candidate discovery for the next generation of malaria vaccines.Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection aga The Human Cytomegalovirus UL116 Gene Encodes an Envelope Glycoprotein Forming a Complex with gH Independently from gL Platelet-derived growth factor-α receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer.Monoclonal Antibodies to Different Components of the Human Cytomegalovirus (HCMV) Pentamer gH/gL/pUL128L and Trimer gH/gL/gO as well as Antibodies Elicited during Primary HCMV Infection Prevent Epithelial Cell Syncytium Formation.Functional screening for anti-CMV biologics identifies a broadly neutralizing epitope of an essential envelope protein Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.Expressing anti-HIV VRC01 antibody using the murine IgG1 secretion signal in Pichia pastoris.Human cytomegalovirus: taking the strain.Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus.The role of structural proteomics in vaccine development: recent advances and future prospects.Cytomegalovirus Vaccines: Current Status and Future Prospects.Genetic Stability of Bacterial Artificial Chromosome-Derived Human Cytomegalovirus during Culture In Vitro.Strategies to control human cytomegalovirus infection in adult hematopoietic stem cell transplant recipients.The proteome of human cytomegalovirus virions and dense bodies is conserved across different strains.Expression of the human cytomegalovirus pentamer complex for vaccine use in a CHO system.Chemokines encoded by herpesviruses.Comparison of homologous and heterologous prime-boost vaccine approaches using Modified Vaccinia Ankara and soluble protein to induce neutralizing antibodies by the human cytomegalovirus pentamer complex in mice.Anti-Infectious Human Vaccination in Historical Perspective.The pentameric complex drives immunologically covert cell-cell transmission of wild-type human cytomegalovirus.What Are the Most Powerful Immunogen Design Vaccine Strategies? Reverse Vaccinology 2.0 Shows Great Promise.Identification of a Continuous Neutralizing Epitope within UL128 of Human Cytomegalovirus.Analytic Vaccinology: Antibody-Driven Design of a Human Cytomegalovirus Subunit Vaccine.Exploiting 2A Peptides to Elicit Potent Neutralizing Antibodies by a Multi-Subunit Herpesvirus Glycoprotein Complex.Phenotype and specificity of T cells in primary human cytomegalovirus infection during pregnancy: IL-7Rpos long-term memory phenotype is associated with protection from vertical transmission.Progress toward Development of a Vaccine against Congenital Cytomegalovirus Infection.Active evolution of memory B-cells specific to viral gH/gL/pUL128/130/131 pentameric complex in healthy subjects with silent human cytomegalovirus infection.Neutralization of Human Cytomegalovirus Entry into Fibroblasts and Epithelial Cells.Advancing our understanding of protective maternal immunity as a guide for development of vaccines to reduce congenital cytomegalovirus infections.Immune responses to congenital cytomegalovirus infection.Dissecting human antibody responses: useful, basic and surprising findings.Fine-mapping the interaction between DC-SIGN and the cytomegalovirus envelope glycoprotein B.Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.

P2860

Q26745798-FEE4DD17-C044-4CC3-B4B4-7270334F73DE Q28075274-4B11B67D-1127-4AB5-A532-7F25D653F56F Q28550400-19512EEF-9BD7-42CF-86C8-1DD7ADDEBCD7 Q33558900-FCD0B64A-82EA-47C6-B7F5-E65ACA2301EB Q35913890-CC11094F-3026-46FE-AA90-20E75955D74C Q36084954-EE7D9F57-4A32-48D7-93CF-67155010DF2F Q36281094-9BB8A926-F228-4231-8292-AC940CC0D36B Q36413834-99EB1CB1-0531-4351-A854-2DF19A764F2A Q36633558-647BA768-55C8-4D60-9F54-4AE048004B4F Q36878894-22DA86DC-35D5-4857-8AC6-AB41EF9A9A76 Q37032510-952E7E25-CF24-45BD-9029-223EC52B4F88 Q37073289-B12D76F9-0FCF-42A7-A8CC-E40975C8FC7B Q37519151-50DFBF39-9058-4CD4-8932-88F53DA3B37C Q37707461-82DCF789-6817-4152-88F3-3EF27B6DE531 Q37721762-DAD9575B-A98F-406F-B5FF-AABBB7179630 Q38430703-C865F34A-3659-459B-AB67-7E04A27B4C71 Q38602178-43590A59-EA61-4FB1-AF25-33B9A3B8FCE1 Q38682335-55C3C9C5-9F28-4C4B-9327-58AA23165BD0 Q38791353-6C9C6B72-AE2A-4A2B-92CB-F32FEC0C6D93 Q38796870-B710958B-B2B5-48FD-B50D-B046BA55B6AF Q38835171-456C418B-82EB-45C6-B9EF-48FF5E50267E Q38904564-07FABFDD-2C85-4D50-92D9-B53F04FE5EEE Q38997531-BDDE20AF-C31C-4083-B235-35DFA2100D17 Q40067378-54E4A5F8-13F9-42CB-8E26-BDEED2CB31BC Q40091454-60147378-1473-486C-A858-073F1C031670 Q40129444-B901205A-96F7-4578-AE0E-31364E8DE50A Q40190061-161EB116-5EC6-4FC9-82D4-C3EF1F0AEAA0 Q40346058-FB76A8D0-8B22-4E26-B076-0F66823B142A Q40375876-80EE21CB-5CB0-4506-946A-3995E1B41DFB Q40715812-7C05BB42-8FED-4D81-9A77-C24D4BCB4BC2 Q41921854-BA8C8EA2-464E-4F6F-B830-0FF9A163C85E Q45851061-5DE257C7-81A7-4AAB-94DF-8C2B305A38D7 Q47115255-8446B29C-E096-406D-AA51-8D4FD59238D6 Q47135919-1E29D099-33FF-47DF-814B-204A8CD174B2 Q47167247-F0FAC907-20CC-4121-87C9-2EDA8CEB5786 Q47546281-8642556A-71D2-4BC6-A2E5-07BAFD850330 Q47559622-4344E8CC-290C-4449-BFC4-3872900895FC Q48023106-7D231CFA-F208-4222-BCC3-9BA85D9DE770 Q52323814-2520CADC-138D-4E4D-BF93-ACE0CE428E48 Q52568669-5D95DFBA-A58A-497C-9456-87107528A952

P2860

Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies

http://www.wikidata.org/entity/Q34753135

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Antibody-driven design of a hu ...... potent neutralizing antibodies

@ast

Antibody-driven design of a hu ...... potent neutralizing antibodies

@en

Antibody-driven design of a hu ...... potent neutralizing antibodies

@nl

type

label

Antibody-driven design of a hu ...... potent neutralizing antibodies

@ast

Antibody-driven design of a hu ...... potent neutralizing antibodies

@en

Antibody-driven design of a hu ...... potent neutralizing antibodies

@nl

prefLabel

Antibody-driven design of a hu ...... potent neutralizing antibodies

@ast

Antibody-driven design of a hu ...... potent neutralizing antibodies

@en

Antibody-driven design of a hu ...... potent neutralizing antibodies

@nl

P1433

Q34753135-B6167235-3F99-4980-A8A1-E2CC6CDC6DB6

P1476

Q34753135-BE790820-4F69-4DFC-A37B-FD7F1F9290FC

P2093

Q34753135-1CD7F729-CB1A-431D-8312-8B1A6F633296

Q34753135-3E515DB5-F125-4946-B4E7-23FF44D8E52D

Q34753135-4398E20C-0FD3-4A3A-90D6-6795CAB01D27

Q34753135-56DC5E5A-3C85-46BA-9040-1A25AD9CFB53

Q34753135-5945836D-EB34-49DC-9626-4DEDC0E8AA75

Q34753135-84586623-3E36-4F80-9728-4D6A20A70FB6

Q34753135-944CBECE-F460-4301-9B3B-1B2D8BC0B34B

Q34753135-9BC35126-3926-402E-A364-CBBA4F59B6E9

P2860

Q34753135-05925277-7566-4547-9C71-EEC5315B8D5C

Q34753135-0A15231C-B17C-4ECC-AC30-6CE1B5E339D1

Q34753135-0B977D6A-B3BC-4369-AC31-5C0D730EA9E0

Q34753135-1B36988C-04C5-45E7-8275-CD6FD4CDABA5

Q34753135-1B67BF49-F2A7-4D9D-96CE-91C7E1560DAA

Q34753135-23E35F7B-CF1F-4F32-A91C-073376A4E175

Q34753135-34D4756D-7859-4539-BB0A-D0215CA726AB

Q34753135-399FE753-7563-4CAA-B25E-80510813CD17

Q34753135-425933F0-7405-456B-BD47-86048AA520B3

Q34753135-52D6DDD5-072C-4012-981C-C89B16F21B02

P304

Q34753135-6F889430-4C21-41DF-AA83-233A1063B2AB

P31

Q34753135-3071B66C-4290-4AFC-83F2-BC2EB526EE56

P356

Q34753135-C3982C3A-088A-4FBF-A1E2-6CC6F8719C2C

P407

Q34753135-AB829922-F506-4ED7-BF66-9D9534743443

P433

Q34753135-6EF0ED6F-EB38-42D4-A7EC-15AE4A072259

P478

Q34753135-589F074E-3508-4C67-8172-E4C45380CEED

P50

Q34753135-017FA1A2-09EB-49C1-8A22-0375A1BD7060

Q34753135-2DB8046D-DED8-4ACB-BF16-8E203ED5B938

Q34753135-D1173659-3748-4EB6-9F26-8D5E1276E777

Q34753135-E3940ED3-6475-4204-A282-104816A05EE2

Q34753135-E5504A65-AE9A-403B-A68E-2EF891E99DE9

P577

Q34753135-E7C2DAC1-F8A3-4194-AF94-3CCB3799366B

P5875

Q34753135-7C352CAA-AB9B-4367-B961-0A340126E053

P698

Q34753135-183FC815-9F86-44F4-8D5C-11BECF91352D

P921

Q34753135-4A627C67-2D2A-405A-B6EE-C9E865C8B9C6

Q34753135-8EB8F050-6AB1-4A98-8D87-F016968D12F7

P932

Q34753135-5BA336E7-32CD-4BDE-8F36-BCCFF4E3B5F6

P356

PNAS.1415310111

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Antibody-driven design of a hu ...... potent neutralizing antibodies

@en

P2093

Antonio Lanzavecchia

http://www.w3.org/2001/XMLSchema#string

Dario Fuschillo

http://www.w3.org/2001/XMLSchema#string

Davide Corti

http://www.w3.org/2001/XMLSchema#string

Federica Sallusto

http://www.w3.org/2001/XMLSchema#string

Giuseppe Gerna

http://www.w3.org/2001/XMLSchema#string

Gloria Agatic

http://www.w3.org/2001/XMLSchema#string

Jessica Marcandalli

http://www.w3.org/2001/XMLSchema#string

Silvia Preite

http://www.w3.org/2001/XMLSchema#string

P2860

Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex.

Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant

A human cytomegalovirus gO-null mutant fails to incorporate gH/gL into the virion envelope and is unable to enter fibroblasts and epithelial and endothelial cells

B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies.

Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism

Herpes virus fusion and entry: a story with many characters.

Broadly neutralizing antiviral antibodies.

Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee.

P304

17965-17970

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1415310111

http://www.w3.org/2001/XMLSchema#string

P407

P433

50

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Daniele Lilleri

Simone Becattini

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269171568

http://www.w3.org/2001/XMLSchema#string

P698

25453106

http://www.w3.org/2001/XMLSchema#string

P921

Cytomegalovirus

P932

4273412

http://www.w3.org/2001/XMLSchema#string